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Previous studies revealed high incidence of acquired N-glycosylation sites acquired 
N-glycosylation sites in RNA transcripts encoding immunoglobulin heavy variable region 
(IGHV) 3 genes from parotid glands of primary Sjögren’s syndrome (pSS) patients. In this 
study, next generation sequencing was used to study the extent of ac-Nglycs among 
clonally expanded cells from all IGVH families in the salivary glands of pSS patients. RNA 
was isolated from parotid gland biopsies of five pSS patients and five non-pSS sicca 
controls. IGHV sequences covering all functional IGHV genes were amplified, sequenced, 
and analyzed. Each biopsy recovered 1,800–4,000 unique IGHV sequences. No dif-
ference in IGHV gene usage was observed between pSS and non-pSS sequences. 
Clonally related sequences with more than 0.3% of the total number of sequences per 
patient were referred to as dominant clone. Overall, 70 dominant clones were found 
in pSS biopsies, compared to 15 in non-pSS. No difference in percentage mutation in 
dominant clone-derived IGHV sequences was seen between pSS and non-pSS. In pSS, 
no evidence for antigen-driven selection in dominant clones was found. We observed a 
significantly higher amount of ac-Nglycs among pSS dominant clone-derived sequences 
compared to non-pSS. Ac-Nglycs were, however, not restricted to dominant clones or 
IGHV gene. Most ac-Nglycs were detected in the framework 3 region. No stereotypic 
rheumatoid factor rearrangements were found in dominant clones. Lineage tree analysis 
showed in four pSS patients, but not in non-pSS, the presence of the germline sequence 
from a dominant clone. Presence of germline sequence and mutated IGHV sequences in 
the same dominant clone provide evidence that this clone originated from a naïve B-cell 
recruited into the parotid gland to expand and differentiate locally into plasma cells. The 
increased presence of ac-Nglycs in IGHV sequences, due to somatic hypermutation, 
might provide B-cells an escape mechanism to survive during immune response. We 
speculate that glycosylation of the B-cell receptor makes the cell sensitive to environ-
mental lectin signals to contribute to aberrant B-cell selection in pSS parotid glands.
Keywords: sjögren syndrome, B-cell, n-glycosylation, heavy chain, parotid gland, next generation sequencing
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inTrODUcTiOn
Primary Sjögren’s syndrome (pSS) is clinically characterized by 
complaints of dry mouth and dry eyes (sicca complaints), which 
are associated with the presence of periductal lymphoid infiltrates 
in the salivary and lacrimal glands. From a pathogenic point of 
view, B-cell hyperactivity is a hallmark of the disease (1). This 
is reflected by the presence of elevated serum levels of IgG in 
patients with pSS, as well as by the presence of autoantibodies, 
such as anti-Ro/SSA and anti-La/SSB autoantibodies, and rheu-
matoid factor (RF) (2, 3).
The periductal infiltrate of the salivary glands harbors many 
B-cells, which even can form ectopic germinal centers (GCs), and 
there is a profound increase in the number of IgG plasma cells (4). 
Mucosa-associated lymphoid tissue (MALT) lymphomas develop 
frequently in the parotid glands of patients with pSS (1, 5). B-cell 
hyperactivity is further revealed by the presence of clonal popula-
tions of B-cells and plasma cells in the minor (labial) and major 
(parotid) salivary gland tissue of pSS patients (6–10). Nearly all 
IgG and IgA encoding genes derived from clonally related cells 
contain somatic mutations and, thus, are thought to originate 
from post-GC memory B-cells and plasma cells (9–11). The 
reason for the considerable clonal expansion of B-cells in pSS is 
not known, but proliferation and survival mediated by enhanced 
signaling through the B-cell receptor (BCR) may be involved. 
This presumption is in line with the observation that both naïve 
and memory B-cells in peripheral blood of pSS patients express 
increased levels of Bruton’s tyrosine kinase, a molecule that is 
critically involved in BCR signaling (12). The elevated levels of 
B-cell associated cytokines, such as BAFF, APRIL, IL-6, and IL-21 
present in serum and saliva of these patients, may further sup-
port the development and persistence of these clonal B-cell and 
plasma cell populations (13–21).
In our previous study (10), the analysis of the mutation patterns 
of the immunoglobulin heavy chain variable 3 genes (IGHV3) 
revealed no evidence that antigen selection plays a major role 
in clonal B-cell expansions in the parotid gland of pSS patients. 
This observation may indicate that alternative driving forces and 
selection pressures are active in these clonal expansions. One 
such driving force might be the presence of newly acquired sugar 
moieties of the immunoglobulins expressed by B-cells as has 
been shown for follicular lymphoma (22–24). These lymphomas 
more frequently show acquired N-glycosylation sites (ac-Nglycs), 
within the variable domain of tumor-specific immunoglobulins. 
N-linked glycosylation requires the consensus amino acid (AA) 
motif N-X-S/T (asparagine-X-serine/threonine). We observed 
a higher prevalence of these ac-Nglycs in the IGHV3 encoding 
transcripts derived from IgG (but not in IgA) expressing clones in 
the parotid gland of pSS patients compared to non-pSS sicca con-
trols. Surprisingly, most (>60%) of these ac-Nglycs were situated 
in the framework (FWR) 3 region and not in the complementarity 
determining regions (CDRs) of the immunoglobulin heavy vari-
able region (IGHV) sequences. Ac-Nglycs are not only increased 
in pSS but also in other rheumatoid and non-rheumatoid autoim-
mune diseases as systemic lupus erythematosus (SLE), multiple 
sclerosis, chronic Chagas’ heart disease, and RA (25). In RA, there 
is an increase of ac-Nglycs in the immunoglobulin variable (V) 
region heavy and light chain transcripts from anti-citrullinated 
protein antibody IgG-expressing B-cells (26).
Our previous finding that ac-Nglycs are enriched in IGHV3 
transcripts from clonal expansions of Ig-producing cells in parotid 
glands of pSS patients may point toward a selective advantage for 
B-cells to expand and survive. A question that arises is whether 
these ac-Nglycs are unique for IGHV3 genes or are also seen in 
IGHV genes from other IGHV families. Furthermore, it remains 
to be shown whether ac-Nglycs are restricted to clonally expanded 
B-cells and plasma cells, and to what extent BCRs with ac-Nglycs 
encode for autoantibodies, such as stereotypic RF. Finally, it has 
to be unraveled whether naïve and/or memory B-cells prolifer-
ate and expand to form clones within the microenvironment 
of the salivary gland tissue of pSS patients. Here, we utilize 
next-generation sequencing (NGS) to address the above issues 
regarding clonal expansion of Ig-producing cells in pSS patients.
MaTerials anD MeThODs
Patients
Parotid biopsies of five pSS patients fulfilling the ACR-EULAR 
(27) criteria for pSS (all female; median age 55  years, range 
18–80  years), with clinically a disease duration of less than 
5 years were included for this study. Other inclusion criteria for 
pSS patients in this study were as follows: stimulated whole saliva 
secretion flow >0.15 ml/min, presence of autoantibodies (ANA 
positive, IgM-RF ≥  10  klU/l, or presence of anti-SSA/anti-SSB 
autoantibodies).
In addition, five parotid biopsies of patients with sicca com-
plaints were included as non-pSS sicca controls (all females; 
median age 66  years, range 59–75  years). These non-pSS sicca 
controls have the same subjective complaints of dry mouth and 
dry eyes as pSS patients, but they do not fulfill the ACR-EULAR 
criteria for pSS. A biopsy of the parotid gland under local anes-
thesia was taken as part of the clinical diagnostic work-up for pSS 
(28). Histopathological examination of the parotid glands of all 
five control patients revealed normal histology of the glandular 
tissue. After analysis of all data, we excluded non-pSS sicca con-
trol 2 because we observed a large clone of >640 members (31% 
of the total non-pSS sequences). Because we could not rule out 
the presence of malignancies in the parotid gland, or the presence 
of lymph nodular tissue, this patient was excluded from the study.
Parotid biopsies were originally collected for diagnostic pur-
poses. Usage of these biopsies for research purposes was obtained 
on written informed consent with approval from the medical 
ethical committee of the University Medical Center Groningen, 
Groningen, the Netherlands.
rna isolation and cDna synthesis
Parotid gland biopsies were snap-frozen in liquid nitrogen after 
surgery and cryo-preserved at −80°C until use. RNA was isolated 
from parotid gland samples using a polytron tissue homogenizer 
(Kinematica AG, Littau-Lucerne, Switzerland) in the presence 
of STAT60 RNA reagent (Tel-test Inc., Friendswood, TX, USA) 
according to the manufacturer’s protocol. After isolation RNA 
was purified using the RNeasy Mini System [Clean-up-protocol 
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(#74106, Qiagen, Venlo, the Netherlands)]. RNA quality was 
checked using the Bioanalyzer 2100 system (Agilent) and quanti-
fied using the Qubit1.0-platform (#Q32857, Invitrogen Life 
Technologies, Breda, the Netherlands). cDNA was synthesized 
using Superscript RT-III and oligo-dT primers according to the 
manufacturer’s protocol (#18080-051, Invitrogen).
linear amplification and ngs
Linear amplification of the IGHV genes was based on the pro-
tocol used previously (29, 30) using primer sets (available upon 
request) that covered all functional IGHV genes. Briefly, the 
IGHV region primers contained a primer B sequence required for 
amplicon sequencing (Roche Diagnostics, Mannheim, Germany). 
Amplified products were purified and used in a generic PCR using 
primer B as forward primer and a reverse generic primer specific 
for all functional IGHJ genes, containing primer sequence A.
Samples were again purified, quantified, prepared for 
sequencing according to the manual for amplicon sequencing, 
and sequenced on a Roche Genome Sequencer FLX (titanium 
platform).
The bioinformatics pipeline used to obtain the IGHV 
sequences was done by performing Multiplex Identifier sorting, 
identification of gene segments, and removal of artifacts.
analysis of rearranged immunoglobulin 
genes
The IGHV sequences were analyzed for IGHV gene usage, rear-
rangement, and mutations by aligning them with the human Ig 
set of the IMGT reference directory.1 The V-region, D-region, 
and J-region alleles closest to the reference germline Ig sets 
were assigned to the obtained IGHV sequence. Only produc-
tive sequences (encoding functional proteins) were included in 
this study. IGHV sequences that were out of frame, too short to 
assign junction analysis or sequences with insertions or deletions 
were discarded. One hundred percent identical IGHV sequences 
obtained from a single biopsy were counted as one, because it 
is not possible to discriminate between sequences derived from 
multiple transcripts of the same cell or identical sequences derived 
from different cells. Unique sequences were selected based upon 
≥1 nucleotide difference.
Immunoglobulin heavy variable region sequences with identi-
cal nucleotide sequences at the CDR3, and shared the same VH 
germline gene, were considered as clonally related. Together 
clonally related sequences form a “clone.” Clones were consid-
ered dominant when the number of clonally related sequences 
was ≥0.3% of the total number of unique recovered sequences 
per patient (arbitrarily chosen) of the total number of productive 
sequences obtained from a single biopsy.
To examine whether the IGHV sequences encode for stereo-
typic RF BCRs, we analyzed the IGHV sequences for the pres-
ence of stereotypic RF VH/JH rearrangements, combined with 
VH-CDR3 AA sequence homology to stereotypic RF VH-CDR3 
AA sequences (11, 31, 32). Screening for VH-CDR3 AA homol-
ogy was performed using the NCBI Protein-BLAST algorithm 
1 http://www.imgt.org.
(search for short nearly exact matches).2 Criteria used for homol-
ogy were ≥60% AA homology and a length difference between 
the VH-CDR3 sequences not exceeding three AA (32).
analysis of clonal expansion
To gain understanding of the origin of the clonal expansion 
of B-cells in the parotid gland, lineage trees were created 
from clonally related IGHV sequences using the algorithm of 
the IgTree© (33). Briefly, IGHV sequences from a dominant 
clone together with the germline sequence were aligned using 
ClustalW software.3 The output alignment was used as input 
in IgTree©. The output tree file is visualized by Graphviz 2.38. 
The root of the tree is the putative germline sequence and the 
clonally related IGHV sequences are assigned to either leaves 
or internal nodes of the tree. Each tree node represents a single 
mutation separating the sequences. Missing sequences are 
artificially added by IgTree©.
analysis of selection Pressures
Selection pressure analysis of the IGHV sequences belonging 
to a dominant clone was studied using the online Bayesian 
Estimation of Antigen-Driven Selection in Immunoglobulin 
Sequences (BASELINe) program. This program uses statistical 
algorithms based on analysis of somatic mutation patterns of the 
IGHV sequences to predict the selection pressure which shape 
the IGHV repertoire of Ig-producing cells. The distribution of 
replacements versus silent (R/S) mutations, in both CDRs and 
FWRs is counted separately and compared against the expected 
frequency. BASELINe aggregates the selection strength of dif-
ferent sequences within a single experimental group and to 
compare the selection pressures between different experimental 
groups (34).
Prediction of acquired n-glycosylation 
sites
Ac-Nglycs were predicted on the basis of the translated AA 
sequences of the IGHV sequences (including the CDR3 region) 
using the NetN-glyc 1.0 online server.4 The server uses artifi-
cial neural networks to examine the context of the N-X-S/T 
(asparagine-X-serine/threonine) motif in the IGHV sequences. 
We used the restriction that X could be any AA except proline, as 
it precludes N-glycosylation due to steric hindrance. Criteria for 
accepting ac-Nglycs used were as follows: potential >0.5 and jury 
agreement ≥5/9. The ability of the software program to predict 
actual N-glycosylation sites has an overall accuracy of 76%.
statistical analysis
All statistical analyses were performed using GraphPad Prism 
software (version 3.0). Statistical comparisons of data from 
pSS patients and non-pSS sicca controls were carried out using 





FigUre 1 | Percentage of IGVH gene usage in the parotid gland biopsies of pSS patients compared to those from non-pSS sicca controls.
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resUlTs
no Major Differences Found in Vh-gene 
Usage of ig-Producing cells in Parotid 
glands of pss and non-pss sicca
A total of 15.756 unique IGHV sequences were collected from 
five parotid biopsies of pSS patients (1.815–4.039 per biopsy) and 
11.834 unique IGHV sequences in the 4 biopsies of non-pSS sicca 
controls (2.673–3.191 per biopsy).
No significant differences in the usage of various VH genes 
among the IGHV sequences derived from pSS and non-pSS sicca 
biopsies were observed except for VH3-72 (Figure 1). The latter 
was significantly (p = 0.0268) more frequently used in non-pSS 
sicca (median 1.17% IQR; 0.64–2.07%) than in pSS (median 
FigUre 2 | Percentage of germline (≤1 nucleotide difference from GL gene) 
encoded IGHV sequences in parotid gland biopsies of pSS patients and 
non-pSS sicca controls.
FigUre 3 | Clonal expansion of Ig-producing cells in the biopsies of the parotid salivary gland of pSS patients and non-pSS sicca controls. (a) Number of dominant 
clones present in the parotid gland per patient. (B) Number of IGHV sequences per dominant clone.
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0.18% IQR; 0.08–0.40%) biopsies. The CDR3 lengths of the IGHV 
sequences between the two patient groups were also similar (data 
not shown).
higher Frequency of germline ighV 
sequences in Parotid glands of pss 
Patients
Next, we analyzed the presence of somatic hypermutations 
among the IGHV sequences amplified from cDNA of parotid 
glands of individual pSS patients and non-pSS sicca controls. 
IGHV sequences with ≥1 nucleotide difference with the closest 
reference germline gene were considered to be mutated as a con-
sequence of somatic hypermutation. A significant (p = 0.0159) 
higher percentage of germline encoded IGHV sequences was 
found among sequences obtained from the parotid gland of 
pSS patients (Figure  2; pSS median 3.9% IQR: 2.6–8.2%, non-
pSS sicca median 0.8% IQR: 0.4–1.0). The higher percentage of 
germline encoded IGHV genes reflects the presence of more 
naïve B-cells in the parotid gland of pSS patients compared to 
the parotid gland of non-pSS sicca controls. With respect to the 
mutation frequency of the mutated sequences we observed that 
pSS IGHV sequences contained significantly (p  <  0.0001) 
lower numbers of mutations than the non-pSS sicca sequences: 
6.5% (IQR: 5.17–9.48% per IGHV sequence) and 7.3% (IQR: 
4.17–8.62% per IGHV sequence), respectively.
increased clonal expansion of ig-
Producing cells in Parotid glands  
of pss Patients
To compare the level of clonal expansion of Ig-producing cells 
in parotid glands of pSS patients and non-pSS sicca controls, 
we examined the number of dominant clones present in each 
sample. IGHV sequences were considered to be derived from 
clonally related cells when the nucleotide sequence of the CDR3 
regions was identical and shared the same VH germline gene. 
The number of dominant clones in parotid gland biopsies was 
significantly higher in pSS patients, compared to non-pSS sicca 
controls (p =  0.0159) (Figure  3A). In pSS patients, there were 
between 6 and 22 dominant clones per biopsy, whereas in non-
pSS sicca controls this was only between 2 and 4. In total, 70 
dominant clones were observed in pSS parotid gland biopsies; 
whereas in non-pSS sicca biopsies, a total of 11 dominant clones 
was detected (Figure 3A). We did not see differences in clone size 
of these dominant clones between pSS patients and non-pSS sicca 
controls (Figure 3B).
no signs of antigenic selection Pressure 
on ig-Producing cells in the Parotid gland 
of pss Patients
In order to study whether antigen selection plays a role in the 
development of the dominant clones, we used BASELINe. With 
this tool, possible antigen selection can be established based on 
the basis of the analysis of somatic mutation patterns (replace-
ment versus silent mutations). Analysis of IGHV sequences 
derived from the dominant clones of the non-pSS sicca controls 
showed positive selection pressures in the CDRs (CDR1 and 
CDR2) and negative selection pressures in the FWRs (FWR1, 
FWR2, and FWR3) (Figure 4). Such a selection pressure profile 
is characteristic for antigen-driven clonal expansion. In marked 
contrast with the non-pSS sicca controls, significantly altered 
selection pressures were seen in IGHV sequences of dominant 
clones derived from pSS patients. The IGHV sequences of pSS 
FigUre 4 | The selection pressures on IGHV sequences derived from dominant clones in pSS patients and non-pSS controls. All individual sequences from the 
dominant clones from pSS and non-pSS control parotid gland biopsies were inserted into the BASELINe program and the selection strength of both groups were 
compared. The figure is obtained as output data from the BASELINe program. The red line in the upper left plot represents the selection strength of the pSS 
sequences in the complementarity determining regions (CDRs). The blue line represents the (negative) selection strength in the framework (FWR) regions. In the 
lower right plot, the red line represents the selection strength of the non-pSS control sequences in the CDRs and the blue line the strength in the FWRs. The lower 
left plot is an overlay plot in which the solid line is the selection strength for pSS and the dashed line for non-pSS. Significance of differences in selection pressures 
was calculated both for CDRs and FWR regions between pSS and non-pSS samples in the upper right plot.
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patients demonstrated negative selection pressures in the CDRs, 
whereas selection pressures of the FWRs were even more nega-
tive than seen in non-pSS sicca controls (Figure 4). These data 
indicate that the formation of dominant Ig-producing clones in 
pSS patients is not typically antigen-driven and that alternative 
mechanisms might be involved in the establishment of clones in 
the salivary gland from pSS patients.
higher incidence of acquired 
n-glycosylation sites in ighV  
sequences of pss Patients
A possible alternative selection mechanism that could be opera-
tional during B-cell expansion in the salivary gland of pSS patients 
could be lectin binding to glycosylated Ig (35). Glycosylation 
sites can be acquired during somatic hypermutation processes of 
IGHV genes (10, 25, 26). We, therefore, analyzed the presence of 
ac-Nglycs in the IGHV sequences from the dominant clones. The 
percentage of dominant-clone-derived sequences, containing at 
least one ac-Nglyc, was significantly higher (p = 0.0159) in pSS 
patients, compared to non-pSS sicca controls (Figure 5A; median 
pSS 14.8% IQR: 9.8–23.8%, median non-pSS sicca 1.6% IQR: 0.0–
5.4%). In total, 180 IGHV sequences out of 1,223 (~15%) IGHV 
pSS sequences that belonged to dominant clones contained 189 
ac-Nglycs (some sequences contained two or three ac-Nglycs); 
whereas in non-pSS sicca controls, this number was substantially 
lower: only 3 out of 133 (~2%) clonally related IGHV sequences 
contained ac-Nglycs.
FigUre 5 | Incidence of ac-Nglycs in IGHV sequences in the salivary parotid 
gland biopsies. (a) The percentage of dominant clone-derived IGHV 
sequences containing at least one ac-Nglycs are shown per patient.  
(B) The percentage of glycosylated non-dominant clone-derived sequences 
per patient and (c) the percentage glycosylated sequences from all  
obtained IGHV (including dominant and non-dominant clone-derived  
IGHV sequences) sequences are depicted per patient.
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To examine whether these Nglycs are restricted to IGHV 
sequences from dominant clones, we compared the percentage 
IGHV sequences containing an ac-Nglyc not belonging to the 
dominant clones obtained from pSS patient biopsies to those from 
non-pSS sicca control biopsies. Again, a significantly increased 
percentage (p =  0.0317) of N-glycosylated IGHV sequences in 
pSS was observed (Figure 5B; median pSS is 13.8% IQR: 10.4–
14.4%, median non-pSS sicca is 8.1% IQR: 5.4–10.0%). When we 
did not discriminate between dominant and non-dominant clone-
derived IGHV sequences, there still was a significant difference 
in percentage IGHV sequences with ac-Nglyc between pSS and 
non-pSS sicca (Figure 5C; median pSS is 15.4% IQR: 11.7–18.6%, 
median non-pSS sicca is 8.4% IQR: 6.2–10.7%). These findings 
suggest that Nglycs acquired during somatic hypermutation are 
not restricted to sequences from dominant clones.
Preferential acquired n-glycosylation 
sites in FWr3 regions of ighV  
sequences from pss Patients
Subsequently, we analyzed the location of the ac-Nglycs in the 
IGHV sequences derived from the dominant clones. Of the 180 
IGHV sequences from pSS patient biopsies, 121 sequences were 
encoded by VH3 genes (67%), 56 sequences by VH4 genes (31%), 
and 3 sequences by VH5 genes (2%) in line with the different 
number of IGVH genes in the respective IGVH gene families. In 
non-pSS sicca controls, two of the IGHV sequences derived from 
dominant clones containing ac-Nglycs were encoded by VH3 
genes and one by VH4. The majority of ac-Nglycs in pSS patients 
were the result of a replacement mutation in the FWR3 region: 
115 out of 189 (61%) ac-Nglycs were located in the FWR3 region. 
The remaining 74 (39%) ac-Nglycs were located in the CDR 
compartment (CDR1 or CDR2). No ac-Nglycs were observed in 
FWR1 or FWR2. In the IGHV sequences derived from non-pSS 
sicca controls, all three ac-Nglycs were located in the CDRs (Table 
S1 in Supplementary Material).
Further analysis showed that most (66%) of the 84 ac-Nglycs 
in IGHV3 sequences were generated by an AA change at posi-
tion 84 in the FWR3 region. There was also a high frequency 
(39%) of 22 ac-Nglycs in the FWR3 of IGHV4 sequences at AA 
position 90.
These data suggest the presence of hot-spots for ac-Nglycs in 
certain IGHV genes, particularly in the FWR3 region. At these 
sites, single change in nucleotide can lead to ac-Nglycs due to the 
composition of the flanking nucleotides.
naïve B-cells Present in Dominant clones 
of the Parotid glands of pss Patients
To study clonal evolution in relation to ac-Nglycs, the IGHV 
sequences belonging to a dominant clone were implemented into 
the algorithm of IgTree©. Mutations leading to new ac-Nglycs 
could be found at every level of the lineage tree constructed from 
the clonally related IGHV sequences of the various dominant 
clones from the pSS patients; an example of a lineage tree of a 
dominant clone-derived from a parotid gland of a pSS patient 
is shown in Figure  6. This observation suggests that muta-
tions leading to ac-Nglycs are not a necessary event for clonal 
expansion.
Analysis of the lineage trees also showed that in four out five 
pSS patients, a clone was found that comprised the original, 
unmutated, germline sequence among the observed IGHV 
sequences. Such clones were not observed in non-pSS sicca 
controls. The presence of both the germline root sequence and 
mutated IGHV sequences within the same dominant clone pro-
vide evidence that this clone developed from a naïve B-cell that 
was recruited into the parotid gland where it underwent local 
expansion and somatic hypermutation. We found no differences 
in trunk length and path length indicating that there is no dif-
ference in affinity and selection threshold in the lineage trees 
generated from dominant clones of pSS compared to non-pSS 
sicca (data not shown). Based on these two parameters, we could 
not discriminate in the diversification history between pSS and 
non-pSS.
stereotypic rF rearrangements Present 
in ighV sequences from Parotid gland  
of pss Patients
Parotid gland MALT lymphomas frequently express BCRs, char-
acterized by a striking AA sequence homology to the IGHV-CDR3 
of stereotypic RFs. These RFs are encoded by typical combina-
tions of restricted IGHV and IG kappa V gene rearrangements. 
Here, we focused on the IGHV rearrangements. Five groups of 
somatically mutated stereotypic RF BCRs have been identified 
(11, 31, 32). Stereotypic RF rearrangements were not found in 
dominant clones from both pSS and non-pSS sicca. Analysis of all 
IGHV sequences derived from the parotid glands of pSS and non-
pSS sicca revealed only very few stereotypic RF sequences in three 
out of five pSS patients and none in non-pSS sicca controls. Both 
in pSS patient 3 (pSS3) and 4 (pSS4), VH3-7/JH3 rearrangements 
were found with CDR3s that were homologous to stereotypic to 
V3-7-RFs. In pSS3, 31 of 4,039 IGHV sequences were encoded by 
this rearrangement. Within these 31 sequences, a total of 4 sets 
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of clonally related sequences were detected with 2, 4, 8, and 10 
members, respectively. The CDR3 regions of all these sequences 
were nearly identical, with differences ranging from one to 
three AAs, suggesting that the 31 sequences probably belong to 
the same clone. In the biopsy of patient pSS4, 5 of 3,229 IGHV 
sequences harbored the VH3-7/JH3 rearrangement, homologous 
to V3-7-RF. These five sequences exhibited some minor differ-
ences in the CDR3 regions, and thus also may belong to a single 
clone. Patient pSS5 harbored only one IGHV sequence with a 
VH1-69/JH4 rearrangement that was homologous to stereotypic 
WOL-RFs. None of the IGHV sequences that were homologous 
to stereotypic RFs contained ac-Nglycs. The data indicate that 
stereotypic RFs are occasionally present in parotid glands of pSS 
patients.
DiscUssiOn
With NGS technology, we showed, in agreement with oth-
ers, that large numbers of Ig-producing clones are present in 
the glandular tissue (6, 7, 9, 36, 37) of pSS patients reflecting 
the characteristic B-cell hyperactivity in these patients (1). 
Importantly, with NGS, we were able to demonstrate now the 
presence of unmutated root/founder sequence from which 
dominant clones arise in the parotid gland of pSS patients. 
Another main finding was that we found no indications that 
antigen selection plays a role in generation of these clones. We 
did, however, observe an increase in the number of ac-Nglycs in 
both clonally related and not clonally related IGHV transcripts 
of pSS patients, as a result of the somatic hypermutations. Thus, 
alternative driving forces and/or selection mechanisms might 
be involved in the survival and expansion of B-cells in the 
development of pSS.
Origin of B-cell clones in the  
Parotid gland
Little is known about the origin of the large number of B-cell clones 
found in parotid glands of pSS patients. One possible explanation 
is that these clones arise from CD27+ memory B-cells that enter 
the salivary glands, where they subsequently clonally expand 
(37, 38). We observed that in the parotid glands of pSS patients (but 
not in non-pSS sicca controls) dominant clones were present that 
were comprised of both unmutated (germline) IGHV sequences 
and somatically hypermutated sequences. The unmutated 
sequence is most likely derived from a naïve B-cell that migrated 
into the parotid gland. Here, the naïve B-cell underwent local 
proliferation and somatic hypermutation, leading to the forma-
tion of a clone. Naïve IGHV sequences were significantly less seen 
in the parotid gland biopsies of non-pSS sicca controls (Figure 2). 
The presence of only mutated IGHV sequences in the dominant 
clones from non-pSS sicca controls suggests local expansion from 
memory cells. However, due to the small amount of dominant 
clones in non-pSS sicca controls, we cannot completely exclude 
the possibility of clonal expansion from naïve B-cells in non-pSS 
sicca controls. Just as we cannot exclude that in pSS patients part 
of the clones still might arise from mutated memory cells that 
enter the parotid gland and expand.
An obvious site for this expansion and somatic hypermuta-
tion are the (ectopic) GCs that can be present in the periductal 
infiltrates of the salivary glands. Similar to regular GCs in 
peripheral lymphoid organs, these ectopic GCs are composed of 
activated B-cells, T-cells, and follicular dendritic cell networks 
(1, 4, 39–41). Whether GCs are involved in the formation of 
dominant clones in parotid glands is, however, questionable. 
First, only a minor proportion (~25%) of the biopsies of pSS 
patients exhibit GCs in the periductal infiltrate (4), whereas 
all pSS patients exhibit clonally expanded Ig-producing clones. 
Histopathological examination of pSS parotid biopsies revealed 
GCs in only one of the five patients studied. Although not for-
mally proven, it is thus rather unlikely that GCs are involved in 
formation of dominant clones in parotid glands of pSS patients. 
Second, somatic hypermutation in classical GCs is associated 
with stringent antigen selection guided by immune complexes 
trapped on the surface of follicular dendritic cells (42). Analysis 
of the mutation patterns (in terms of silent versus replacement 
mutations) of the IGHV sequences derived from dominant 
clones in pSS parotid glands did not show any evidence for 
antigen-driven selection of Ig-sequences. Apparently, at least 
part of the Ig-producing clones is derived from naïve B-cells that 
are recruited to the salivary gland during inflammation, where 
they are activated, proliferate, somatically hypermutate, and 
undergo isotype switching in a GC-independent fashion in the 
absence of antigen-driven selection. This is in marked contrast 
to non-pSS sicca controls. The IGHV sequences of dominant 
clones in these disease controls are clearly the result of a clas-
sical antigen-selection process. However, GCs are absent in the 
non-pSS sicca control salivary glands and no clonally related 
unmutated sequences are found. A plausible explanation for this 
might be that isotype (IgA) switched CD27+ memory B-cells are 
formed in a classical way in GCs located at distal, mucosal sites. 
These pre-selected memory cells might enter the parotid gland 
as IgA+ memory B-cells to further proliferate during which they 
acquire some additional mutations, and finally differentiate to 
plasmablasts and plasmacells. This scenario resembles what has 
been proposed for gut IgA plasma cells in humans (43).
increased acquired n-glycosylation sites 
in ighV sequences in pss
We did not find indications for signs of antigen selection in the 
dominant clones in pSS patients. However, we observed a sig-
nificantly higher incidence of ac-Nglycs in the IGHV sequences 
derived from the dominant clones in parotid gland tissue from 
pSS patients compared to non-pSS sicca controls. We observed 
that the majority of the ac-Nglycs were present in certain hot-
spots, in particular in the FWR3 region of IGHV3 and IGHV4 
FigUre 6 | Lineage tree constructed by IgTree© from IGHV sequences of a dominant clone-derived from a parotid gland of a pSS patient. The blue dots depict the 
IGHV sequences obtained from the parotid gland biopsies. The gray dots represent theoretical IGHV sequences generated by the algorithm of the IgTree© program. 
The red circled dots represent obtained IGHV sequences with ac-Nglycs. The red circles depict the mutation responsible for ac-Nglycs. GL: germline sequence.
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sequences. A single nucleotide change at this spot during the 
somatic hypermutation process could already result in ac-Nglycs. 
The increased frequency of ac-Nglycs is, however, not restricted 
for IGHV sequences of the dominant clones. The higher incidence 
of ac-Nglycs seems to be a common phenomenon in the total pool 
of IGHV sequences obtained from the salivary gland biopsies of 
pSS patients (Figure  5). Moreover, ac-Nglycs have been found 
in RA (26) and other non-rheumatic autoimmune diseases. We 
even obtained evidence in a meta-analysis of published IGVH 
genes from patients with autoimmune diseases and controls that 
acquiring of new Nglycs in variable regions of immunoglobulin 
genes is a common feature in patients with autoimmune diseases 
(25). The relevance of this Fab glycosylation in autoimmunity still 
needs to be further investigated.
Fc-glycosylated antibodies have been found in anti-neutrophil 
cytoplasmic antibody (ANCA)-associated systemic vasculitis 
(AAV), SLE, pSS, and RA. Fc-glycosylation patterns were asso-
ciated with disease activity and severity and outcome (44–49). 
In RA also glycosylated Fab antibodies have been found (44, 
50–52). Glycosylation of the Fab fragment of Ig can influence 
the affinity for antigens (53, 54), but it also has been postulated 
in AAV that Fab glycosylation can have effector functions. 
Highly Fab glycosylated ANCA IgG had an increased ability to 
induce the respiratory burst in neutrophils in  vitro compared 
to the non-glycosylated ANCA IgG. However, the role of Fc 
glycosylation cannot completely be excluded in this assay (50). 
Sometimes Fab glycosylation even can correlate with disease 
activity (44, 50). Of note, the described effects of glycosylation 
are at the protein level and the ac-Nglycs in our NGS study are 
at transcription level and, therefore, potential sites for glycosyla-
tion. A major difference between Fc and Fab glycosylation is that 
Fc glycosylation is genetically encoded while Fab glycosylation 
seems to be introduced as a result of somatic hypermutation of 
the IGV-region.
The introduction of new Nglycs in the IGHV sequences in pSS 
may offer Ig expressing cells an alternative selection mechanism 
to escape from the classical selection mechanism in GCs. This 
is strengthened by lack of evidence for antigen-driven selection 
of the IGHV sequences and the explicit tendency for ac-Nglycs 
to occur within the FWRs. Binding of the glycosylated BCR 
with glycan receptors, such as lectins, in the vicinity of the 
receptor could rescue B-cells from cell death. Coelho et al. (35) 
demonstrated that recombinant lectin domains of the mannose 
receptor or DC-SIGN binds in vitro to mannosylated Igs of fol-
licular lymphoma cells to trigger BCR-mediated signaling events 
(Ca2+flux). Binding of lectins to glycosylated Igs was presumed 
to lead to survival and even to expansion of lymphoma cells. 
Lectins are widespread and are both expressed by many cell types, 
such as T-cells, NK  cells, macrophages, dendritic cells, and by 
micro-organisms (55–58). This makes inflamed parotid tissue the 
ideal microenvironment for lectins to bind to the glycosylated Igs.
rheumatoid Factor
The increased capacity of clonal expansion of B-cells in the exocrine 
glands of pSS patients significantly increases the risk of developing 
MALT-lymphoma (5, 59, 60). A characteristic feature of MALT-
lymphoma is the expression of BCR with RF reactivity. It has been 
shown by Bende et al. (31) that at least 40% of the cases of salivary 
gland MALT lymphoma, express BCRs with strong CDR3 homology 
to RFs (stereotypic RFs). They further showed that these stereotypic 
RF clones were only sporadically present in SS labial salivary glands 
(11). Analysis of our parotid gland sequence data confirmed the 
observations in the labial salivary glands (11). Although we observed 
some stereotypic RF rearrangements in three out of five pSS patients 
RF rearrangements were not observed in any of the dominant clones. 
The observation of a relative small number of sequences with ste-
reotypic RF in the parotid gland tissue of pSS patients suggest that 
antigen-specific triggers are needed for these rare B-cells to expand 
and transform to neoplastic MALT lymphoma cells.
In summary, we demonstrate that at least part of the 
Ig-producing clones within the pSS glands are the result 
of local proliferation of naïve unmutated B-cells. The high 
number of Nglycs, acquired in the IGHV sequences during 
somatic hypermutation, may generate a selective advantage 
for Ig-producing B-cells in the parotid gland tissue to survive 
selection mechanisms. The interactions of the (potential) gly-
cans with lectins in the environment of the inflamed parotid 
gland tissue could offer (autoreactive) B-cells this alternative 
selection mechanism.
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